Home › Funds › BNP PARIBAS › GILD
BNP PARIBAS position in GILD
GILEAD SCIENCES INC · Health Care
BNP PARIBAS reported holding 158,394 shares of GILD (GILEAD SCIENCES INC) in its Q3 2026 13F filing — a position valued at US$23.7M, representing 0.57% of its reported portfolio and ranking #36 among its reported holdings. BNP PARIBAS has disclosed GILD holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How BNP PARIBAS's GILD position evolved
BNP PARIBAS first disclosed a stake in GILD in Q1 2024 at 78,605 shares (US$5.8M). The position peaked in Q3 2026 at 158,394 shares, worth US$23.7M. Across 11 filings, BNP PARIBAS increased the stake 6 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 158,394 shares valued at US$23.7M — an increase of 39,723 shares quarter over quarter.. Notable position changes include a 33% increase in Q4 2025 (shares rose 14% over the following quarter), a 33% increase in Q3 2026 (shares rose 14% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 78.61K | $5.76M | New |
| Q2 2024 | 81.42K | $5.58M | Add |
| Q3 2024 | 77.39K | $6.49M | Reduce |
| Q4 2024 | 74.40K | $6.87M | Reduce |
| Q1 2025 | 85.34K | $9.56M | Add |
| Q2 2025 | 85.50K | $9.47M | Hold |
| Q3 2025 | 69.47K | $7.71M | Reduce |
| Q4 2025 | 92.55K | $11.36M | Add |
| Q1 2026 | 98.34K | $13.70M | Add |
| Q2 2026 | 118.67K | $14.99M | Add |
| Q3 2026 | 158.39K | $23.68M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GILD and 13F data
GILD (GILEAD SCIENCES INC) is a Health Care company. 34 other funds we track also report a position in GILD — the largest reported positions include Fidelity Management & Research (FMR) (US$8.45B), Capital World Investors (US$5.18B), Capital World Investors (US$5.18B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GILD
- Fidelity Management & Research (FMR) 66.87M sh · $8.45B · Q2 2026
- Capital World Investors 40.99M sh · $5.18B · Q2 2026
- Capital World Investors 40.99M sh · $5.18B · Q2 2026
- Invesco Ltd 39.82M sh · $5.03B · Q2 2026
- PRICE T ROWE ASSOCIATES INC /MD/ 30.00M sh · $3.79B · Q2 2026
- Dodge & Cox 23.68M sh · $2.99B · Q2 2026
- DODGE & COX 23.68M sh · $2.99B · Q2 2026
More on BNP PARIBAS
FAQ
How long has BNP PARIBAS held GILD?
BNP PARIBAS has disclosed GILD holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is BNP PARIBAS's current position in GILD?
As of Q3 2026, BNP PARIBAS holds 158.39K shares of GILD (GILEAD SCIENCES INC), valued at $23.68M, representing 0.57% of its reported portfolio and ranking #36.
Has BNP PARIBAS been buying or selling GILD?
In the latest 13F filing (Q3 2026), BNP PARIBAS increased its position in GILD. The position peaked in Q3 2026 at 158.39K shares.
Which other funds hold GILD?
Other major institutional holders of GILD include Fidelity Management & Research (FMR), Capital World Investors, Capital World Investors, among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.